Dirk Kosemund

Identification of Atuveciclib (BAY 1143572), the First Highly Selective, Clinical PTEFb/CDK9 Inhibitor for the Treatment of Cancer

Ulrich Lücking, Arne Scholz, Philip Lienau et al. · ChemMedChem · 2017 · 176 citations · Full text

Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity

Antje M. Wengner, Gerhard Siemeister, Marcus Koppitz et al. · Molecular Cancer Therapeutics · 2016 · 117 citations · Full text

Oncology, Medicine, Potent Antitumor Activity +14

Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer

Ulrich Lücking, Dirk Kosemund, Niels Böhnke et al. · Journal of Medicinal Chemistry · 2021 · 68 citations · Full text

Lead Optimization Efforts, Oncology, Novel Therapy +13

Treating Cancer by Spindle Assembly Checkpoint Abrogation: Discovery of Two Clinical Candidates, BAY 1161909 and BAY 1217389, Targeting MPS1 Kinase

Volker Schulze, Ulrich Klar, Dirk Kosemund et al. · Journal of Medicinal Chemistry · 2020 · 53 citations · Full text

Abstract 984: Identification of potent and highly selective PTEFb inhibitor BAY 1251152 for the treatment of cancer: from p.o. to i.v. application via scaffold hops

Ulrich Luecking, Arne Scholz, Dirk Kosemund et al. · Cancer Research · 2017 · 28 citations

Ic50 Cdk9, Scaffold Hops, Cancer Biology +18